Scarica l'app Stockscreener
73.14
4.15%
-3.17
Dopo l'orario di chiusura:
73.14
Precedente Chiudi:
$76.31
Aprire:
$76.69
Volume 24 ore:
250.74K
Relative Volume:
1.42
Capitalizzazione di mercato:
$808.90M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+4.35%
1M Prestazione:
+34.18%
6M Prestazione:
+199.75%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$71.01
$77.50
Intervallo di 1 settimana:
$65.93
$77.67
Portata 52W:
$11.17
$77.67
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
125 STRAFFORD AVE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
73.14 | 813.11M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Trend analysis for Palvella Therapeutics Inc. this week2025 Key Lessons & Reliable Breakout Forecasts - newser.com
Can Palvella Therapeutics Inc. rally from current levelsPortfolio Risk Summary & Pattern Based Trade Signal System - newser.com
Is Palvella Therapeutics Inc. meeting your algorithmic filter criteriaEarnings Miss & Advanced Swing Trade Entry Alerts - newser.com
What Fibonacci levels say about Palvella Therapeutics Inc. reboundWeekly Stock Recap & Accurate Entry/Exit Alerts - newser.com
Can Palvella Therapeutics Inc. stock rebound after recent weaknessRisk Management & Verified Technical Signals - newser.com
Multi factor analysis applied to Palvella Therapeutics Inc.July 2025 Reactions & Momentum Based Trading Ideas - newser.com
Reversal indicators forming on Palvella Therapeutics Inc. stock2025 Stock Rankings & Safe Entry Trade Reports - newser.com
Can Palvella Therapeutics Inc. stock withstand economic slowdownRisk Management & Weekly Watchlist for Consistent Profits - newser.com
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $75.50 Consensus PT from Analysts - Defense World
Palvella Receives Second Year of FDA Grant Funding for Phase 3 Qtorin Trial - MarketScreener
U.S. FDA awards year two funds to Palvella's phase 3 Selva trial - MarketScreener
U.S. Food and Drug Administration Awards Year Two Proceeds - GlobeNewswire
U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics’ Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - Yahoo Finance
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 5.9%What's Next? - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Palvella Therapeutics Inc. reversing from oversold territoryJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
Palvella Therapeutics' (PVLA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Canaccord Genuity raises Palvella Therapeutics stock price target to $90 on new indication - Investing.com Canada
Canaccord Genuity Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
Can trapped investors hope for a rebound in Palvella Therapeutics Inc.Quarterly Profit Review & Risk Adjusted Buy and Sell Alerts - newser.com
Applying big data sentiment scoring on Palvella Therapeutics Inc.Swing Trade & Weekly Top Performers Watchlists - newser.com
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients - MSN
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics Names David W. Osborne, Ph.D. as Chief Innovation Officer - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 6.6% HigherHere's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Hits New 1-Year HighHere's Why - MarketBeat
Tick level data insight on Palvella Therapeutics Inc. volatilityMarket Rally & AI Driven Price Predictions - newser.com
Can Palvella Therapeutics Inc. (PI6) stock deliver consistent EPS growthMarket Weekly Review & AI Powered Buy/Sell Recommendations - newser.com
How to interpret RSI for Palvella Therapeutics Inc. stock2025 Price Targets & Long-Term Capital Growth Strategies - newser.com
How to build a custom watchlist for Palvella Therapeutics Inc.Earnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Will Palvella Therapeutics Inc. bounce back from current supportTrade Analysis Summary & Detailed Earnings Play Alerts - newser.com
LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
Strid Group LLC Lowers Stake in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock beat Nasdaq index returnsWeekly Gains Summary & Step-by-Step Swing Trade Plans - newser.com
Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $80 - 富途牛牛
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
Palvella Therapeutics Inc Azioni (PVLA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| JENKINS GEORGE M | Director |
Apr 09 '25 |
Buy |
20.13 |
2,500 |
50,325 |
183,171 |
| JENKINS GEORGE M | Director |
Dec 18 '24 |
Buy |
12.93 |
4,000 |
51,720 |
180,671 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):